KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Amgen (AMGN) Other Non-Current Liabilities (2016 - 2025)

Historic Other Non-Current Liabilities for Amgen (AMGN) over the last 17 years, with Q4 2025 value amounting to $2.7 billion.

  • Amgen's Other Non-Current Liabilities rose 1451.68% to $2.7 billion in Q4 2025 from the same period last year, while for Dec 2025 it was $2.7 billion, marking a year-over-year increase of 1451.68%. This contributed to the annual value of $2.7 billion for FY2025, which is 1451.68% up from last year.
  • Latest data reveals that Amgen reported Other Non-Current Liabilities of $2.7 billion as of Q4 2025, which was up 1451.68% from $2.6 billion recorded in Q3 2025.
  • Amgen's 5-year Other Non-Current Liabilities high stood at $7.0 billion for Q1 2021, and its period low was $2.3 billion during Q3 2024.
  • Moreover, its 5-year median value for Other Non-Current Liabilities was $4.6 billion (2023), whereas its average is $4.6 billion.
  • Its Other Non-Current Liabilities has fluctuated over the past 5 years, first plummeted by 5020.75% in 2024, then skyrocketed by 1473.68% in 2025.
  • Amgen's Other Non-Current Liabilities (Quarter) stood at $6.6 billion in 2021, then decreased by 12.69% to $5.8 billion in 2022, then dropped by 18.71% to $4.7 billion in 2023, then crashed by 49.81% to $2.3 billion in 2024, then grew by 14.52% to $2.7 billion in 2025.
  • Its last three reported values are $2.7 billion in Q4 2025, $2.6 billion for Q3 2025, and $2.5 billion during Q2 2025.